{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T22:56:54Z","timestamp":1771455414666,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,1,12]],"date-time":"2002-01-12T00:00:00Z","timestamp":1010793600000},"content-version":"vor","delay-in-days":225,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:p>We evaluated the cytomegalovirus (CMV) serostatus as a risk factor for survival and treatment\u2010related mortality (TRM) in 125 patients allografted from an unrelated donor between 1994 and 1999. All patients received pretransplant<jats:italic>in vivo<\/jats:italic>T\u2010cell depletion using rabbit anti\u2010thymocyte globulin (ATG). Only one patient had primary graft failure and severe grade III\/IV graft\u2010versus\u2010host disease occurred in 14% of the patients. The overall survival (OS) at 3\u2003years was 70% for CMV\u2010negative patients (<jats:italic>n<\/jats:italic>\u2003=\u200376) and 29% in the seropositive cohort (<jats:italic>n<\/jats:italic>\u2003=\u200349) (<jats:italic>P<\/jats:italic>\u2003&gt;\u20030\u00b7001). In multivariate analyses, CMV seropositivity remained an independent negative prognostic factor for OS\u00a0(RR: 2\u00b71; CI: 1\u00b72\u20133\u00b78;<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7014), apart from age\u2003&gt;\u200320\u2003years (RR: 2\u00b774; CI: 1\u00b72\u20133\u00b78;<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7004) and late leucocyte engraftment (RR: 2\u00b74; CI: 1\u00b72\u20134\u00b79;<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7015). The TRM for all patients was 27%. Despite monitoring for CMV antigenaemia and preemptive therapy with ganciclovir when reactivation occurred, seropositive patients had a three times higher risk of fatal treatment\u2010related complications than seronegative patients. In multivariate analyses, CMV seropositivity remained the strongest independent negative factor for TRM (RR: 5\u00b73; CI: 1\u00b79\u201314\u00b76;<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7002), followed by age\u2003&gt;\u200320\u2003years (RR: 4\u00b78; CI: 1\u00b73\u201318\u00b71;<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b702) and delayed leucocyte engraftment (RR: 3\u00b76; CI: 1\u00b72\u201311;<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b702). The TRM was identical in seropositive patients with (<jats:italic>n<\/jats:italic>\u2003=\u200327) or without (<jats:italic>n<\/jats:italic>\u2003=\u200322) CMV reactivation (44% versus 50%). We conclude that CMV seropositivity, despite preemptive ganciclovir therapy and even without reactivation, is a major negative prognostic factor for survival as well as for TRM in unrelated stem cell transplantation using pretransplant<jats:italic>in vivo<\/jats:italic>T\u2010cell depletion with ATG.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.02849.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:34:39Z","timestamp":1047364479000},"page":"1060-1071","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment\u2010related mortality in stem cell transplantation from unrelated donors using pretransplant<i>in vivo<\/i>T\u2010cell depletion with anti\u2010thymocyte globulin"],"prefix":"10.1111","volume":"113","author":[{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatjana","family":"Zabelina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Renges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Stute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Schrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Kabisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Schafhausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Jaburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius","family":"L\u00f6liger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Hinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel R.","family":"Zander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0198-8859(90)90071-V"},{"key":"e_1_2_6_3_1","first-page":"155","article-title":"CMV antigenemia after allogeneic bone marrow transplantation: correlation of CMV\u2010antigen positive cell number with transplant\u2010related mortality","volume":"16","author":"Bacigalupo A.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_4_1","first-page":"290a","article-title":"Potent effect of ATG as part of the conditioning in matched unrelated donor (MUD) transplantation","volume":"92","author":"Baurmann H.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198509263131301"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V88.10.4063.bloodjournal88104063","article-title":"Cytomegalovirus pp65 antigenemia\u2010guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation","volume":"88","author":"Boeckh H.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1992.tb06479.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V95.7.2240","article-title":"Increased transplant\u2010related morbidity and mortality in CMV seropositive patients despite highly effective prevention of CMV disease after allogeneic T\u2010cell depleted stem cell transplantation","volume":"95","author":"Broers A.E.C.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702165"},{"key":"e_1_2_6_10_1","first-page":"347","article-title":"Early reactivation of cytomegalovirus and high risk of interstitial pneumonia following T\u2010cell depleted BMT for adults with hematological malignancies","volume":"18","author":"Couriel D.","year":"1996","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox D.R.","year":"1972","journal-title":"Journal of the Royal Statistical Society (B)"},{"key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1182\/blood.V86.4.1636.bloodjournal8641636","article-title":"Unrelated donor bone marrow transplantation: influence of HLA\u2010A and B incompatibility on outcome","volume":"6","author":"Davies S.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood.V86.7.2815.2815","article-title":"Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration of side effects of antiviral therapy after bone marrow transplantation","volume":"86","author":"Einsele H.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood.V83.9.2392.2392","article-title":"Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand?","volume":"83","author":"Forman S.J.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1128\/jcm.30.5.1232-1237.1992","article-title":"Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp. 65) for optimal quantitation of human cytomegalovirus antigenaemia","volume":"30","author":"Gerna G.","year":"1992","journal-title":"Journal of Clinical Microbiology"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92330-1"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-6-806"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-3-199302010-00003"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1182\/blood.V92.12.4581","article-title":"Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft versus host disease and graft rejection","volume":"92","author":"Hale G.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804023381405"},{"key":"e_1_2_6_21_1","first-page":"387","article-title":"In vivo\/ex vivo T cell depletion of GvHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT","volume":"15","author":"Hertenstein B.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199303043280901"},{"issue":"1","key":"e_1_2_6_24_1","first-page":"87","article-title":"State of art review. Bone marrow transplantation treatment for\u00a0storage diseases","volume":"10","author":"Krivit W.","year":"1992","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770000269"},{"key":"e_1_2_6_26_1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1182\/blood.V81.2.543.543","article-title":"Unrelated donor marrow transplantation for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program","volume":"81","author":"McGlave P.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_6_27_1","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood.V95.7.2219","article-title":"Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years experience of the National Marrow Donor Program","volume":"95","author":"McGlave P.B.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/153.3.478"},{"key":"e_1_2_6_29_1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1182\/blood.V86.3.1228.1228","article-title":"The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft versus host disease prophylaxis regimen of ciclosporine, methotrexate, and prednisone","volume":"86","author":"Nademanee A.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.4.1606.bloodjournal8641606"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.2307\/2344317"},{"key":"e_1_2_6_32_1","first-page":"825","article-title":"1994 Consensus Conference on acute GvHD\u2010grading","volume":"15","author":"Przepiorka K.M.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(05)80168-4"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810223391701"},{"key":"e_1_2_6_35_1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1128\/jcm.35.3.741-744.1997","article-title":"Minimal effect of delayed sample processing on results of quantitative PCR for cytomegalovirus DNA in leucocytes compared to results of an antigenaemia assay","volume":"35","author":"Sch\u00e4fer P.","year":"1997","journal-title":"Journal of Clinical Microbiology"},{"key":"e_1_2_6_36_1","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1182\/blood.V89.11.4226","article-title":"Transplantation of marrow cells from unrelated donors for treatment of high risk acute leukaemia. Effect of leukaemic burden, donor HLA\u2010matching and marrow cell dose","volume":"89","author":"Sierra J.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_37_1","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1182\/blood.V86.9.3590.bloodjournal8693590","article-title":"Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T\u2010cell depletion: major prognostic impact of HLA class I identity between donor and recipient","volume":"86","author":"Spencer A.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_38_1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1128\/jcm.32.4.997-1003.1994","article-title":"Comparison of PCR and pp. 65 antigenaemia assay with quantitative shell vial culture for detection of cytomegalovirus in blood leucocytes from solid\u2010organ transplant recipients","volume":"32","author":"Storch G.A.","year":"1994","journal-title":"Journal of Clinical Microbiology"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702216"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-3-199302010-00004"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701745"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02849.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02849.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.02849.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T13:46:45Z","timestamp":1733579205000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.02849.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1046\/j.1365-2141.2001.02849.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02849.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]},"assertion":[{"value":"2002-01-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}